# Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease

> **NCT02177786** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 334 (actual)

## Conditions studied

- Diabetic Kidney Disease

## Interventions

- **DRUG:** Selonsertib
- **DRUG:** Placebo to match selonsertib

## Key facts

- **NCT ID:** NCT02177786
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2016-07
- **Final completion:** 2016-08
- **Target enrollment:** 334 (ACTUAL)
- **Last updated:** 2019-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02177786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02177786, "Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02177786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*